Lacosamide

證據等級: L5

預測適應症: 10 個

Lacosamide: From Focal Epilepsy to Manic Bipolar Affective Disorder

One-Sentence Summary

Lacosamide (Vimpat®) is an antiseizure medication approved for the treatment of focal (partial onset) epilepsy. The TxGNN model predicts it may be effective for Manic Bipolar Affective Disorder, with 1 clinical trial and 14 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Focal epilepsy (partial onset seizures)
Predicted New Indication	Manic Bipolar Affective Disorder
TxGNN Prediction Score	99.96%
Evidence Level	L2
Taiwan Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, formal mechanism of action data is not available in this evidence pack. Based on published literature, lacosamide is a third-generation antiseizure medication that works primarily by selectively enhancing the slow inactivation of voltage-gated sodium channels (Nav1.x), stabilizing hyperexcitable neuronal membranes and reducing repetitive neuronal firing. A secondary mechanism involves binding to collapsin response mediator protein 2 (CRMP2), which modulates ion channel trafficking and synaptic connectivity in limbic circuits.

The mechanistic rationale is strong: lamotrigine and carbamazepine — both sodium channel modulators in the same pharmacological class — are established first-line treatments for bipolar disorder. Lacosamide shares the Nav1.x modulation mechanism, suggesting a plausible mood-stabilizing pathway. Moreover, CRMP2 modulation may independently influence synaptic plasticity in limbic regions implicated in mood regulation, providing a second mechanistic bridge to affective disorders.

Clinically, the progression of evidence follows a coherent arc: observational studies first noted incidental improvements in depressive and anxious symptoms in epilepsy patients receiving lacosamide; a retrospective 30-day comparison study (PMID 30251375) and a 12-week open-label pilot trial (PMID 33666402) then directly examined lacosamide in bipolar disorder patients without epilepsy, both reporting positive signals; a Phase 3 RCT (NCT07412132) is now actively recruiting. An important caveat: existing clinical evidence primarily addresses bipolar depressive episodes, not manic episodes specifically — the disease-phase distinction is clinically critical and represents a gap in the current evidence base.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT07412132	Phase 3	Recruiting	40	Randomized, double-blind, parallel-group trial evaluating lacosamide as augmentation to first- or second-line treatments in moderate-to-severe bipolar depressive episodes (Types I & II). Note: n=40 is substantially below typical Phase 3 standards (≥200); statistical power is a concern. NCT ID format is atypical and requires verification.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33666402	2021	Open-label Pilot Trial	J Clin Psychopharmacol	12-week pilot study demonstrating efficacy and tolerability of lacosamide for bipolar depression — earliest prospective clinical signal
30251375	2018	Retrospective Comparison	Psychiatry Clin Neurosci	30-day comparison of lacosamide vs other antiepileptics in hospitalized BD patients without epilepsy; positive findings in a real-world psychiatric setting
29253680	2018	Prospective Multicenter	Epilepsy Behav	Lacosamide improved depression and anxiety scores in focal refractory epilepsy patients; effects appear partly independent of seizure control, suggesting intrinsic psychotropic activity
28845834	2017	Case Report	Acta Bio-Medica	Clinical mood stabilization with lacosamide in a patient with mood disorder, PTSD, and fronto-temporal epilepsy; discusses Nav slow-inactivation as a membrane-stabilizing mechanism in psychiatry
30275630	2018	Adverse Event Report	Indian J Psychol Med	⚠️ Safety signal: lacosamide precipitated neutropenia in a BD patient with comorbid epilepsy — haematological monitoring indicated
32693579	2020	Review	ACS Chem Neurosci	CRMP2 as a druggable neurological target; explains lacosamide's CRMP2-binding and its relevance to ion channel trafficking and limbic synaptic plasticity
38304661	2024	Case Report	Cureus	Complex management of a pregnant BD Type I patient with comorbid epilepsy and PNES; demonstrates real-world use of lacosamide in psychiatric–neurological overlap
29957667	2018	Review	Ther Drug Monit	TDM 2018 update noting lacosamide's expanding clinical use beyond epilepsy, including pain and bipolar disorder
37782796	2023	Structural Study	PNAS	Cryo-EM structures of human Nav1.7 bound to antiseizure drugs (riluzole, lamotrigine); provides mechanistic framework for how Nav-targeting AEDs achieve their shared pharmacological effects
40777679	2025	Case Report	Cureus	Xylazine withdrawal in a patient with comorbid bipolar disorder; lacosamide used as part of management — illustrates BD–epilepsy clinical overlap context

Safety Considerations

Please refer to the package insert for safety information.

Literature-derived safety signal: PMID 30275630 documents a case of lacosamide-precipitated neutropenia in a patient with bipolar disorder and comorbid epilepsy. Baseline and periodic haematological monitoring (CBC with differential) is advisable if lacosamide is used in psychiatric populations.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Lacosamide shares a mechanistic drug class with lamotrigine and carbamazepine — both established first-line bipolar disorder treatments — and preliminary clinical data from a retrospective study and a 12-week open-label pilot trial have demonstrated positive signals. An active Phase 3 RCT confirms growing clinical commitment to this hypothesis. However, the existing evidence base predominantly addresses bipolar depressive episodes, whereas the TxGNN-predicted indication is the manic phase, leaving a direct evidence gap for manic episode management.

To proceed, the following is needed:

Completion and full publication of NCT07412132 Phase 3 results (with enrollment size adequacy review)
Direct clinical evidence specifically for manic episode (not only depressive episode) efficacy
Full mechanism of action documentation from DrugBank (DG002 data gap)
Safety monitoring protocol including CBC with differential (neutropenia risk)
Assessment of Taiwan regulatory pathway (TFDA) for off-label use or new indication application, given current zero-authorization status
Head-to-head comparison design vs. established BD treatments (lithium, valproate, lamotrigine) to define competitive clinical positioning
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.